LANTERN PHARMA ANNOUNCES PEER-REVIEWED PUBLICATION OF PHASE 1A LP-184 DATA IN RECURRENT GLIOBLASTOMA, SUPPORTING A PHASE 1B/2A COMBINATION TRIAL WITH SPIRONOLACTONE

Reuters · 2d ago

Please log in to view news